Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.5K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.5K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Seizures l: Introduction01:20

Seizures l: Introduction

36
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
36
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human brain changes after first psilocybin use.

Nature communications·2026
Same author

Serotonergic psychedelics for depression: A comprehensive overview.

International review of neurobiology·2025
Same author

Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study.

Archives of suicide research : official journal of the International Academy for Suicide Research·2024
Same author

Psilocybin and Other Classic Psychedelics in Depression.

Current topics in behavioral neurosciences·2023
Same author

Canalization and plasticity in psychopathology.

Neuropharmacology·2022
Same author

Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21.

Psychopharmacology·2021
Same journal

Biological and social rhythm differences, daily melatonin secretion and psychiatric symptoms in healthy adults.

International journal of psychiatry in clinical practice·2026
Same journal

Diagnostic utility of pan-immune inflammation value in drug-naïve first-episode psychosis.

International journal of psychiatry in clinical practice·2026
Same journal

Examining neuroretinal alterations in autism spectrum disorder: a systematic review of OCT and OCT-A studies.

International journal of psychiatry in clinical practice·2026
Same journal

Depressive symptoms in patients with schizophrenia spectrum disorders and the impact on treatment motivation and satisfaction.

International journal of psychiatry in clinical practice·2026
Same journal

Predictors of premature treatment termination in an inpatient programme for women with PTSD and/or eating disorders.

International journal of psychiatry in clinical practice·2026
Same journal

Evaluation of haematological parameters in patients with first-episode psychosis: distinctions between bipolar disorder and schizophrenia spectrum disorders.

International journal of psychiatry in clinical practice·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

11.7K

Do SSRIs prolong seizure duration during ECT?

J Potokar1, S Wilson, D J Nutt

  • 1Psychopharmacology Unit, University of Bristol, UK.

International Journal of Psychiatry in Clinical Practice
|June 20, 2014
PubMed
Summary
This summary is machine-generated.

Selective serotonin re-uptake inhibitors (SSRIs) may prolong seizure duration during electroconvulsive therapy (ECT). Further research is needed to confirm this finding and assess its clinical impact.

Keywords:
Electroconvulsive therapyseizure durationselective serotonin re-uptake inhibitors

More Related Videos

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.9K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K

Related Experiment Videos

Last Updated: Apr 28, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

11.7K
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.9K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K

Area of Science:

  • Neuroscience
  • Psychopharmacology
  • Clinical Psychiatry

Background:

  • Electroconvulsive therapy (ECT) is an effective treatment for severe psychiatric disorders.
  • Antidepressant medications, including selective serotonin re-uptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), are often used in conjunction with ECT.
  • The interaction between antidepressants and ECT, particularly concerning seizure parameters, requires further investigation.

Purpose of the Study:

  • To investigate the effect of SSRIs on seizure duration in patients undergoing ECT.
  • To compare seizure duration in patients treated with SSRIs versus those treated with TCAs or MAOIs.

Main Methods:

  • Retrospective study design.
  • Analysis of seizure duration data from patients who received ECT.
  • Comparison of seizure duration between groups receiving different classes of antidepressants (SSRIs, TCAs, MAOIs).

Main Results:

  • Patients receiving SSRIs exhibited significantly longer seizure durations during ECT compared to those on TCAs and MAOIs.
  • The sample size for the SSRI group was small (n=13).

Conclusions:

  • SSRIs may be associated with prolonged seizure duration during ECT.
  • Further research with larger sample sizes is warranted to validate these findings.
  • The clinical implications of altered seizure duration require investigation.